

# INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY

VOLUME 33, NUMBER 10

OCTOBER 2012

## SHEA/CDC POSITION PAPER

- 965 Surveillance Definitions of Infections in Long-Term Care Facilities: Revisiting the McGeer Criteria** • Nimalie D. Stone, MD; Muhammad S. Ashraf, MD; Jennifer Calder, PhD; Christopher J. Crnich, MD; Kent Crossley, MD; Paul J. Drinka, MD; Carolyn V. Gould, MD; Manisha Juthani-Mehta, MD; Ebbing Lautenbach, MD; Mark Loeb, MD; Taranisia MacCannell, PhD; Preeti N. Malani, MD; Lona Mody, MD; Joseph M. Mylotte, MD; Lindsay E. Nicolle, MD; Mary-Claire Roghmann, MD; Steven J. Schweon, MSN; Andrew E. Simor, MD; Philip W. Smith, MD; Kurt B. Stevenson, MD; Suzanne F. Bradley, MD; for the Society for Healthcare Epidemiology Long-Term Care Special Interest Group
- 978 Commentary: A Significant Step Forward: New Definitions for Surveillance of Infections in Long-Term Care** • Maria Luisa Moro, MD

## SHEA GUIDANCE STATEMENT

- 981 The Use of Live Attenuated Influenza Vaccine (LAIV) in Healthcare Personnel (HCP): Guidance from the Society for Healthcare Epidemiology of America (SHEA)** • Thomas R. Talbot, MD, MPH; Hilary Babcock, MD, MPH; Deborah Cotton, MD, MPH; Lisa L. Maragakis, MD, MPH; Gregory A. Poland, MD; Edward J. Septimus, MD; Michael L. Tapper, MD; David J. Weber, MD, MPH, writing as the SHEA Task Force on Healthcare Personnel Influenza Vaccination

## ORIGINAL ARTICLES

- 984 Outbreak of Carbapenem-Resistant Enterobacteriaceae at a Long-Term Acute Care Hospital: Sustained Reductions in Transmission through Active Surveillance and Targeted Interventions** • Amit S. Chitnis, MD, MPH; Pam S. Caruthers, RN; Agam K. Rao, MD; JoAnne Lamb, MPH; Robert Lurvey, MD, JD; Valery Beau De Rochars, MD, MPH; Brandon Kitchel, MS; Margarita Cancio, MD; Thomas J. Török, MD, MPH; Alice Y. Guh, MD, MPH; Carolyn V. Gould, MD, MSCR; Matthew E. Wise, PhD, MPH
- 993 Device-Associated Infection Rates, Device Utilization, and Antimicrobial Resistance in Long-Term Acute Care Hospitals Reporting to the National Healthcare Safety Network, 2010** • Amit S. Chitnis, MD, MPH; Jonathan R. Edwards, MStat; Phillip M. Ricks, PhD; Dawn M. Sievert, PhD; Scott K. Fridkin, MD; Carolyn V. Gould, MD, MSCR
- 1001 Predictors of Hospital-Acquired Urinary Tract-Related Bloodstream Infection** • M. Todd Greene, PhD, MPH; Robert Chang, MD; Latoya Kuhn, MPH; Mary A. M. Rogers, PhD; Carol E. Chenoweth, MD; Emily Shuman, MD; Sanjay Saint, MD, MPH
- 1008 Personal Protective Equipment Management and Policies: European Network for Highly Infectious Diseases Data from 48 Isolation Facilities in 16 European Countries** • Giuseppina De Iaco, MD; Vincenzo Puro, MD; Francesco Maria Fusco, MD; Stefan Schilling, MD; Helena C. Maltezou, MD; Philippe Brouqui, MD; René Gottschalk, MD; Barbara Bannister, MSc; Hans-Reinhard Brodt, MD; Heli Siikamaki, MD; Christian Perronne, MD; Arne Broch Brantsæter, MD; Anne Lise Fjellet, MD; Giuseppe Ippolito, MD; European Network for Highly Infectious Diseases Working Group



CONTENTS CONTINUED INSIDE

THE OFFICIAL JOURNAL OF THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA

$\frac{20}{200}$	A	1
$\frac{20}{100}$	R E	2
$\frac{20}{70}$	Y O U R	3
$\frac{20}{50}$	E Y E S G O O D	4
$\frac{20}{40}$	E N O U G H T O	5
$\frac{20}{30}$	S P O T T H E	6
$\frac{20}{20}$	M I C R O S C O P I C	7
$\frac{20}{15}$	P A T H O G E N S	8
$\frac{20}{10}$	I N Y O U R F A C I L I T Y ?	9

Seeing is not believing. Quantify your cleanliness.



**3M™ Clean-Trace™**  
Hygiene Management System

Scan to learn more or visit:  
[3M.com/cleantrace/CHE](http://3M.com/cleantrace/CHE)

© 3M 2012. All rights reserved.

3M Infection Prevention Solutions





# INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY

VOLUME 33, NUMBER 10

OCTOBER 2012

CONTENTS CONTINUED FROM COVER

- 1017 Registration of Blood Exposure Accidents in the Netherlands by a Nationally Operating Call Center** • Peter M. Schaeferberger, PhD, MD; Annemarie E. Meiberg, MSc, RN; Janet Warmelts, RN; Sander C. A. P. Leenders, PhD, MD; Paul T. L. van Wijk, PhD
- 1024 Active Surveillance and Decolonization of Methicillin-Resistant *Staphylococcus aureus* on Admission to Neonatal Intensive Care Units in Hong Kong: A Cost-Effectiveness Analysis** • Joyce H. S. You, PharmD, BCPS(AQ-ID); C. Y. Chan, BPharm; M. Y. Wong, BPharm; Margaret Ip, FRCPath, FRCP(Glasg)
- 1031 Epidemiology and Healthcare Costs of Incident *Clostridium difficile* Infections Identified in the Outpatient Healthcare Setting** • Jennifer L. Kuntz, PhD; Eric S. Johnson, PhD; Marsha A. Raebel, PharmD; Amanda F. Petrik, MS; Xiuhai Yang, MS; Micah L. Thorp, DO, MPH; Steven J. Spindel, MD; Nancy Neil, PhD; David H. Smith, PhD
- 1039 Daily Disinfection of High-Touch Surfaces in Isolation Rooms to Reduce Contamination of Healthcare Workers' Hands** • Sirisha Kundrapu, MD; Venkata Sunkesula, MD, MS; Lucy A. Jury, NP; Brett M. Sitzlar, BS; Curtis J. Donskey, MD
- 1043 Laboratory-Confirmed Pandemic H1N1 Influenza in Hospitalized Adults: Findings from the Canadian Nosocomial Infections Surveillance Program, 2009–2010** • Krista Wilkinson, MSc; Robyn Mitchell, MHS; Geoffrey Taylor, MD; Barbara Amihod; Charles Frenette, MD; Denise Gravel, MSc; Allison McGeer, MD; Kathryn N. Suh, MD; Alice Wong, MD; Canadian Nosocomial Infection Surveillance Program
- 1047 An Outbreak of Scabies in Multiple Linked Healthcare Settings in the Netherlands** • Yuki Fukuta, MD; Lloyd G. Clarke, MSc; Ryan K. Sheldahl, PharmD; Marissa M. Pascale, PhD; A. William Pascale, ScD; Yohei Doi, MD, PhD
- 1051 Lack of Seasonality in the Occurrence of Multidrug-Resistant *Acinetobacter baumannii* Complex** • Yuki Fukuta, MD; Lloyd G. Clarke, MSc; Ryan K. Sheldahl, PharmD; Marissa M. Pascale, PhD; A. William Pascale, ScD; Yohei Doi, MD, PhD
- 1053 Clinical Features of Community-Onset *Acinetobacter baumannii* Infections** • Cheol-In Kang, MD; So Yeon Park, MD; Young Eun Ha, MD; Eun-Jeong Joo, MD
- 1059 Diagnostic Bronchoscopy among Intensive Care Unit Patients with Ventilator-Associated Pneumonia** • Anthony J. Russo, MPH; Trent J. Donders, PhD; Eric S. Johnson, PhD; Marsha A. Raebel, PharmD; Vickie M. Brown, RN, MPH; Emily E. Sickbert-Bennett, PhD
- 1063 Laboratory-Confirmed Pandemic H1N1 Influenza in Hospitalized Adults: Findings from the Canadian Nosocomial Infections Surveillance Program, 2009–2010** • Krista Wilkinson, MSc; Robyn Mitchell, MHS; Geoffrey Taylor, MD; Barbara Amihod; Charles Frenette, MD; Denise Gravel, MSc; Allison McGeer, MD; Kathryn N. Suh, MD; Alice Wong, MD; Canadian Nosocomial Infection Surveillance Program
- 1065 Outpatient Healthcare Setting** • Jennifer L. Kuntz, PhD; Eric S. Johnson, PhD; Marsha A. Raebel, PharmD; Amanda F. Petrik, MS; Xiuhai Yang, MS; Micah L. Thorp, DO, MPH; Steven J. Spindel, MD; Nancy Neil, PhD; David H. Smith, PhD
- 1067 Daily Disinfection of High-Touch Surfaces in Isolation Rooms to Reduce Contamination of Healthcare Workers' Hands** • Sirisha Kundrapu, MD; Venkata Sunkesula, MD, MS; Lucy A. Jury, NP; Brett M. Sitzlar, BS; Curtis J. Donskey, MD
- 1069 Laboratory-Confirmed Pandemic H1N1 Influenza in Hospitalized Adults: Findings from the Canadian Nosocomial Infections Surveillance Program, 2009–2010** • Krista Wilkinson, MSc; Robyn Mitchell, MHS; Geoffrey Taylor, MD; Barbara Amihod; Charles Frenette, MD; Denise Gravel, MSc; Allison McGeer, MD; Kathryn N. Suh, MD; Alice Wong, MD; Canadian Nosocomial Infection Surveillance Program
- 1071 Lack of Seasonality in the Occurrence of Multidrug-Resistant *Acinetobacter baumannii* Complex** • Yuki Fukuta, MD; Lloyd G. Clarke, MSc; Ryan K. Sheldahl, PharmD; Marissa M. Pascale, PhD; A. William Pascale, ScD; Yohei Doi, MD, PhD
- 1073 Clinical Features of Community-Onset *Acinetobacter baumannii* Infections** • Cheol-In Kang, MD; So Yeon Park, MD; Young Eun Ha, MD; Eun-Jeong Joo, MD

## CONCISE COMMUNICATIONS

CONTENTS CONTINUED ON NEXT PAGE



# INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY

VOLUME 33, NUMBER 10

OCTOBER 2012

CONTENTS CONTINUED FROM PREVIOUS PAGE

## LETTERS TO THE EDITOR

- 1059 **Review of Evidence for Alcohol-Based Skin Preparation Agents** • AkkeNeel Talsma, PhD, RN, FAAN; Carol E. Chenoweth, MD
- 1061 **Chlorhexidine Does Not Select for Resistance in *Staphylococcus aureus* Isolates in a Community Setting** • Mark D. Johnson, MD, MTM&H; Carey D. Schlett, MPH; Greg A. Grandits, MS; Katrin Mende, PhD; Timothy J. Whitman, DO; David R. Tribble, MD, DrPH; Duane R. Hospenthal, MD, PhD; Patrick R. Murray, PhD
- 1063 **Retrospective Analysis of Culture-Positive Peripherally Inserted Central Catheter Infections at an Academic Medical Center** • Christina Liscynsky, MD; Kurt B. Stevenson, MD, MPH
- 1064 **Surveillance for Influenza Using Hospital Discharge Data May Underestimate the Burden of Influenza-Related Hospitalization** • Deborah A. Williamson, MD; Q. Sue Huang, PhD; Sally A. Roberts, MD; Cameron C. Grant, MD; Colin McArthur, MD; Michael G. Baker, MD
- 1066 **An Analysis of the Accuracy of Physician-Entered Indications on Computerized Antimicrobial Orders** • Jean A. Patel, PharmD; John S. Esterly, PharmD; Marc H. Scheetz, PharmD, MSc; Michael J. Postelnick, RPh



*An Official Publication of the Society for Healthcare Epidemiology of America*

**EDITOR**

Suzanne F. Bradley, MD • Ann Arbor, MI

**DEPUTY EDITOR**

Carol A. Kauffman, MD • Ann Arbor, MI

**SENIOR ASSOCIATE EDITORS**

C. Glen Mayhall, MD • Galveston, TX  
Gina Pugliese, RN, MS • Chicago, IL  
William Schaffner, MD • Nashville, TN

**ASSOCIATE EDITORS**

Ebbing Lautenbach, MD, MPH • Philadelphia, PA  
Preeti N. Malani, MD, MSJ • Ann Arbor, MI  
David Weber, MD, MPH • Chapel Hill, NC

**STATISTICS CONSULTANT**

Rodney L. Dunn, MS • Ann Arbor, MI

**SECTION EDITOR FOR GUIDELINES,  
POSITION PAPERS, AND INVITED REVIEWS**

Carol Chenoweth, MD • Ann Arbor, MI

**MANAGING EDITOR**

Rob Blixt • Chicago, IL

**PAST EDITORS**

*Infection Control*

Richard P. Wenzel, MD, 1980–1990 (vols. 1–11)

*Infection Control and Hospital Epidemiology*

Richard P. Wenzel, MD, 1991–1992 (vols. 12 and 13)

Michael D. Decker, MD, 1993–2001 (vols. 14–22)

Barry M. Farr, MD, 2002–2004 (vols. 23–25)

William R. Jarvis, MD, 2005–2006 (vols. 26 and 27)

**EDITORIAL ADVISORY BOARD**

Miriam Alter, PhD, MD • Galveston, TX  
Deverick Anderson, MD, MPH • Durham, NC  
Anucha Apisarntharak, MD • Pratumthani, Thailand  
Lennox Archibald, MD, FRCP • Alachua, FL  
Hilary Babcock, MD • St. Louis, MO  
Shailen Banerjee, PhD • Atlanta, GA  
Elise M. Beltrami, MD, MPH • Atlanta, GA  
Jo Anne Bennett, RN, PhD • New York, NY  
David Birnbaum, PhD, MPH • Sidney, BC  
Marc Bonten, MD • Utrecht, Netherlands  
Christian Brun-Buisson, MD • Creteil, France  
John P. Burke, MD • Salt Lake City, UT  
David P. Calfee, MD, MS • New York, NY  
Yehuda Carmeli, MD, MPH • Tel Aviv, Israel  
Donald E. Craven, MD • Burlington, MA  
Christopher Crnich, MD, MS • Madison, WI  
Erika D'Agata, MD, MPH • Boston, MA  
Daniel Diekema, MD • Iowa City, IA  
Erik Dubberke, MD, MSPH • St. Louis, MO  
Charles E. Edmiston, Jr., PhD • Milwaukee, WI  
Theodore C. Eickhoff, MD • Denver, CO  
Mohamad Fakhri, MD, MPH • Grosse Pointe Woods, MI  
Jon P. Furuno, PhD • Portland, OR  
Petra Gastmeier, MD • Berlin, Germany  
Jeffrey Gerber, MD, PhD • Philadelphia, PA  
Dale N. Gerding, MD • Hines, IL  
Donald A. Goldmann, MD • Boston, MA  
Nicholas Graves, PhD • Brisbane, Australia  
Donna Haiduvén, RN, PhD, CIC • Tampa, FL  
Anthony D. Harris, MD, MPH • Baltimore, MD  
Elizabeth Henderson, PhD • Calgary, AB

David K. Henderson, MD • Bethesda, MD  
Loreen A. Herwaldt, MD • Iowa City, IA  
Peter N. R. Heseltine, MD • Brea, CA  
John A. Jernigan, MD, MS • Atlanta, GA  
James T. Lee, MD, PhD • St. Paul, MN  
L. Clifford McDonald, MD • Atlanta, GA  
Allison McGeer, MD • Toronto, ON  
Leonard A. Mermel, DO, ScM • Providence, RI  
Robert R. Muder, MD • Pittsburgh, PA  
Linda Mundy, MD • St. Louis, MO  
Joseph M. Mylotte, MD, CIC • Buffalo, NY  
Jan Evans Patterson, MD • San Antonio, TX  
David A. Pegues, MD • Los Angeles, CA  
Eli Perencevich, MD, MS • Iowa City, IA  
Didier Pittet, MD, MS • Geneva, Switzerland  
Issam Raad, MD • Houston, TX  
Manfred L. Rotter, MD, DipBact • Vienna, Austria  
William A. Rutala, PhD, MPH • Chapel Hill, NC  
Lisa Saiman, MD, MPH • New York, NY  
Sanjay Saint, MD, MPH • Ann Arbor, MI  
Sorana Segal-Maurer, MD • Flushing, NY  
Lynne M. Sehulster, PhD • Atlanta, GA  
John A. Sellick, DO • Amherst, NY  
Kent Sepkowitz, MD • New York, NY  
Andrew E. Simor, MD • Toronto, ON  
Philip W. Smith, MD • Omaha, NE  
Kurt Stevenson, MD, MPH • Columbus, OH  
Nimalie Stone, MD • Atlanta, GA  
Thomas Talbot, MD, MPH • Nashville, TN  
Paul Tambyah, MBBS • Singapore  
William Trick, MD • Chicago, IL  
Antoni Trilla, MD, PhD • Barcelona, Spain  
Robert A. Weinstein, MD • Chicago, IL  
Andreas Widmer, MD, MS • Basel, Switzerland  
Marcus Zervos, MD • Detroit, MI

*Infection Control and Hospital Epidemiology* (ISSN 0899-823X) is published monthly by the University of Chicago Press, 1427 E. 60th St., Chicago, IL 60637-2954 (<http://www.journals.uchicago.edu/ICHE/>). The editorial office is in Chicago, Illinois.

**Editorial Office**

Communications should be addressed to the Editor, *Infection Control and Hospital Epidemiology*, 1427 E. 60th St., Chicago, IL 60637-2954; (e-mail: [iche@press.uchicago.edu](mailto:iche@press.uchicago.edu); telephone: 773-702-2538, fax: 773-753-4247). Contributors should consult the Information for Authors, which is available at the journal's Web site.

**Advertising**

Please direct advertising inquiries to Paul Tucker, Breuning Nagle Associates, 59 Grove Street, New Canaan, CT 06840 (e-mail: [paul@bna1.com](mailto:paul@bna1.com); telephone: 847-669-1096, fax: 203-801-0011). Publication of an advertisement in *Infection Control and Hospital Epidemiology* does not imply endorsement of its claims by the Society for Healthcare Epidemiology of America, by the Editor, or by the University of Chicago. Correspondence regarding advertising should be addressed to the advertising office in Chicago.

**Permissions**

Articles may be copied or otherwise reused without permission only to the extent permitted by Sections 107 and 108 of the US Copyright Law. Permission to copy articles for personal, internal, classroom, or library use may be obtained from the Copyright Clearance Center (<http://www.copyright.com>). For all other uses, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale, please contact the Permissions Coordinator, Journals Division, University of Chicago Press, 1427 E. 60th St., Chicago, IL 60637 (e-mail: [journalpermissions@press.uchicago.edu](mailto:journalpermissions@press.uchicago.edu); fax:

773-834-3489). Articles in the public domain may be used without permission, but it is customary to contact the author.

**Subscriptions**

Individual subscription rates for 2012 are \$191. Lower rates for fellows, residents, and students are available at <http://www.journals.uchicago.edu/ICHE>. Individuals have the option to order directly from the University of Chicago Press. Institutional print + electronic and e-only subscriptions are available through JSTOR's Current Scholarship Program and include unlimited online access; rates are tiered according to an institution's type and research output: \$425 to \$1,063 (print + electronic), \$340 to \$884 (e-only). Institutional print-only is \$425. Additional taxes and/or postage for non-U.S. subscriptions may apply. Subscription agent for Japan: Kinokuniya Company, Ltd. Free or deeply discounted access is available in most developing nations through the Chicago Emerging Nations Initiative (<http://www.journals.uchicago.edu/ceni/>).


Please direct subscription inquiries, requests for back issues, and address changes to Journals Division, University of Chicago Press, P.O. Box 37005, Chicago, IL 60637 (e-mail: [subscriptions@press.uchicago.edu](mailto:subscriptions@press.uchicago.edu); telephone: 773-753-3347 or toll-free in the United States and Canada 877-705-1878; fax: 773-753-0811 or toll-free 877-705-1879).

**Postmaster:** Send address changes to *Infection Control and Hospital Epidemiology*, University of Chicago Press, P.O. Box 37005, Chicago, IL 60637-2954.

Periodicals postage paid at Chicago, Illinois, and at an additional mailing office.

Published by the University of Chicago Press, Chicago, Illinois. © 2012 by the Society for Healthcare Epidemiology of America. All rights reserved. This publication is printed on acid-free paper.





# SHEA

The Society for Healthcare  
Epidemiology of America

The SHEA Education & Research Foundation is grateful to the following members who have shown their dedication to the field of healthcare epidemiology and infection prevention through their generous contributions to the Foundation during the 2012 membership year.

### President's Circle (\$500+)

Louise M Dembry  
Susan S Huang  
Timothy Lane  
Mark E Rupp  
August J Valenti  
Anonymous

### Contributor (\$250-499)

Neil O Fishman  
Lisa K Maragakis  
Jan E Patterson  
Lucy Tompkins  
Robert A Weinstein  
Anonymous

### Leader (\$100-249)

George Alangaden  
Kemper K Alston  
Devernick Anderson  
Mary Andrus  
Steven I Aronin  
Edina Avdic  
Hanan H Belkhy  
Gio J Baracco  
Tamar F Barlam  
Katherine L Baumgarten  
Glenn D Badoso  
Matthew J Bizzarro  
William A Bowler  
Jennifer L Bright  
Charles Brummitt  
Ted Butler  
Judith R Campbell  
John L Carpenter  
Graig Charles  
Richard A Chmielewski  
Barbara Clones  
David K Cobb  
Stuart Cohen  
Craig S Conover  
Donald E Craven  
Christopher A Czaja  
Gerald J Dorff  
Robert A Duncan  
Michael B Edmond  
Ernesto D Efron  
Phyllis Flomenberg  
Carol V Freer  
Naohisa Fujita  
Richard Goodman  
Steven M Gordon  
Theodore J Grieshop  
Elizabeth B Hale  
Gregory D Harrington  
Jo-Ann S Harris  
Sandra L Harris  
Stephen G Hausman  
Inga M Himehlright  
David Hirschowitz  
Malivan Honger  
David C Hooper  
Gay E Howard  
Nancy Hutchinson  
Sherif Ibrahim  
David Ikin  
Jennie Johnstone  
Mini Kamboj  
Keith Kaye  
Steven L Keenholz  
Donald J Kennedy  
Guy T Kochvar

Nancy Kollisch  
Kenji Kono  
Tonni Kristensen  
Joanne Langley  
Emil P Lesho  
Deborah Levy  
Robert D Libke  
Evelyn W Lo  
Mark Loeb  
Robert W Lyons  
D. Stewart S MacIntyre  
Kunthorn Malathum  
Julie E Mangione  
Alexandre R Marra  
H R Mattison  
Marc A Mazade  
David B McGehee  
Katherine McGowan  
Lina Mendantais  
Aron Misesne  
Edward A Morales  
Joseph P Myers  
Linda Myers  
Joseph P Myers  
Irving Nachamkin  
Donald M Nielsen  
James T Noble  
Rathel I Nolan III  
Judith A O'Donnell  
Margaret A Pass  
Theodore J Passon  
Trish M Peri  
Russell M Petrak  
Theresa Plaskett  
Richard Porwancho  
Kenneth R Ratzan  
Shirley J Ray  
Deborah K Riley  
Jethro Treas Ritter  
Zachary Rubin  
Cassandra D Salgado  
Felix A Sarubbi  
Kent A Sepkowitz  
Daniel J Sexton  
Samir S Shah  
Ellen E Shelley  
Jasjit Singh  
Priscilla B Sison-Anterex  
Suzanne Smith-Elekes  
Suzanne Smith-Elekes  
Scott Spillmann  
Harold C Standiford  
Donald F Storey  
Kavitha Subramanian  
Theodore T Thompson  
Michael G Van Eten  
Linda L Van Eten  
Nancy Wagner  
W. Scott Warner  
Douglas H Webb  
Stephen C Weber  
Ganesh M Wiener  
Kenneth M Wiener  
Cynthia J Whitener  
Evelyn White  
Deborah S Yokoe  
Stephen R Zeller  
Marcus J Zervos

### Friend (\$50-99)

Elizabeth Abel  
Robert C Aber  
Carl J Abraham Jr  
Odalys Abreu-Lanfranco  
Silvia Acosta-Gnass

Reginaldo Adalberto De Luz  
John S Adams  
Olayinka A Adedayo  
Adedayo Adedeji  
Antonio Adriano-Neto  
Nasir M Ahmad  
Werner C Albrich  
Sharon 'Brie' K Alexander  
Roy J Almeida  
Miriam J Alter  
Andrew W Amador  
Leif P Andersen  
Barbara Anderson  
Daniel J Anderson  
David Andresen  
Robert J Andrews  
Robert J Andrews  
Wu Anhua  
Cynthia J Anneski  
Makoto Aoki  
Matthew J Arduino  
Kathleen M Arias  
Robert C Arman  
Robert W Armstrong  
Jennifer K Arnold  
Jenniffer K Arnold  
Kathryn E Arnold  
Muhammad Saifan Arshad  
Michael S Ashton  
Robert L Altmar  
Paula J Aucoin  
Kathy Aureden  
Charles Awason  
Bertha S Ayi  
Hilary M Babcock  
omer m badahman  
Stephanie Baer  
Yolanda J Ballam  
Robert S Ballmore  
Jeffrey D Band  
Marsha Bardon  
Robert C Barnes  
Sue Barnes  
Raoul Barron  
Scott Barfels  
Judene M Bartley  
Steven N Bass  
Murray D Batt  
Gonzalo Beaman  
Douglas Bechard  
Anne Beck  
Jennifer Becraft  
Anusha Belani  
Zintars G Beldavs  
Tawny Belleau  
Elise M Beltrami  
Shmuel Benenson  
Jamie Bennett  
Solomon M Beraki  
Elie F Barbari  
Don H Berenson  
Luiz E Bermudez  
Mary T Bessessen  
Werner E Bischoff  
Bernard Block  
Susan Bleasdale  
Brigitte Boaretto  
Daniel J Bokan  
Maureen Bolton  
Adam Boris  
Susan E Boruchoff  
Jason Bowling  
John M Boyce  
Zuzanne F Bradley  
Dale W Bratzler

Barbara I Braun  
Barry Brause  
Robert L Brawley  
Patrick J Brennan  
Frank Briggs  
Simone Brisson  
Michelle V Broday  
Steven E Brooks  
Andrew M Bruggen  
Philip P Bruno  
Lou Ann Bruno-Murtha  
Kristina Bryant  
Elizabeth Bryce  
Brian P Buggy  
Patti R Bull  
Robert W Bundzen  
Timothy L Burke  
Mary L Burkett  
Linda J Burton  
Mary T Busowski  
Karin E Byers  
Christine K Cahill  
Jennifer Calder  
David P Calfee  
Denise W Cardo  
Yehuda Carmel  
Yark B Carr  
Maria J Carreon  
Maria A Carrillo-Marquez  
Yehli Gaver  
Yasmin Geinkaya Sardi  
Waiswari Chalappalli  
Michael T Charney  
Archana Chatterjee  
Roz F Cherny  
Luise F Chen  
Carol E Chenoweth  
Raymond Y Chin  
Khami Chokani  
Sfaraz A Choudhary  
George W Christensen  
Wendy Chung  
Wendy Chung  
Mary R Clance  
Herbert W Clegg II  
Susan Coffin  
Raymond A Coghlan  
Matan J Cohen  
P. A Coley  
Stephen M Colodny  
Cristie Columbus  
John M Conly  
Beverly L Connolly  
Brian W Cooper  
Hillary B Cooper  
Sara E Cosgrove  
Nancy G Coulter  
Brian T Courtney  
Tracy Cox  
Valerie A Creswell  
Christopher J Cramer  
James K Crowley  
Denise Cunha  
Margaret Cunningham  
Brian Currie  
Constance J Cutler  
John Czachor  
William A Datzell  
Nizamuddin Damani  
Vanzha Dandavath  
Gwen Davis  
Valeska De Andrade Stempliuk

Jorgelina de Sanctis  
Jean-Winoc Decousser  
H G Deery II  
Timothy H Delitt  
Rebecca Denny  
Stanley C Deressinski  
Jasmine Dhindsa  
Joanne Dixon  
Susan Dolan  
Patrick Dolce  
Susan V Donohue  
Gemma Downham  
David G Driller  
Richard J Duma  
Marylene J Dush  
Richard J Duma  
Wm. C Dunagan  
Dennis E Durieux  
Beth Dziekan  
Stephen C Edberg  
Charles E Edmonson  
Theodore C Eickhoff  
Floyd P Eisenberg  
Cindy Eling  
Katharine Ellingson  
Sean P Elliott  
Richard T Ellison  
Mamoun Elsheikh  
Alexis M Elward  
David L Emanuel  
John M Emmit  
Carol F Encarnacion  
Kylie Enfield  
Judith F English  
Kim S Erlich  
F. Richard Ervin  
Maria C Espiritu-Fuller  
Patricia A Evans  
Mohamad G Fakhri  
Pamela Falk  
Ahmed O Farooq  
Sergio R Filho  
Lori Finkelstein  
Catherine R Fischer  
David T Fisk  
Fidelmis Fitzpatrick  
Silvia S Fonseca  
Barry C Fox  
Henry Framow  
Victoria J Fraser  
Leah W Frederick  
Charles Frenette  
Elizabeth C Frenzel  
Scott K Fridkin  
Candace Friedman  
Teresa M Fulton  
Keiichi Furukawa  
E. Yoko Furuya  
Elizabeth Fuss  
Sylvia Garcia-Houchens  
Moresy Gardner  
Steven E Gardner  
Joseph G Garner  
Kathleen A Gasse  
Petra Gastmeier  
Michael Gaudes  
Daniel J Geha  
Michael S Gelfand  
Angela Gentile  
Dale N Gerding  
Daniel H Gerovich  
Paula Ghazarian  
Jane C Gilbert-Howard  
Joseph Gillis


Michael B Ginsberg  
Aaron E Glatt  
Daniel P Gluckstein  
Angella M Goetz  
Julian Gold  
Marisa Z Gomes  
Blanca E Gonzalez  
Omar Y Gonzalez  
Pamela Goodling  
Edward L Goodman  
K V Gopalakrishna  
Gerald Gordon  
Shelley Gordon  
Jane M Gould  
Marie Gourdeau  
Donald R Graham  
Patti Grant  
Bruno P Granwehr  
William K Green  
Bonnie D Greene  
John N Greene  
Linda Greene  
Peter A Gross  
Pawel Grzesiowski  
Nili Gujadhur  
Adi V Gundalappi  
Judith A Guzman-Cottini  
Janet Haas  
Sarah Haessler  
Patrick G Haggerty  
Matthew C Hall  
Davidson H Hamer  
Robin W Hampton  
Zhuolin Han  
Stephan Harbarth  
James Hargreaves  
Eliane S Haron  
Jane Harper  
Alan A Harris  
Anthony Harris  
Keck Hartman  
Alan I Hartstein  
Kathryn M Hawkins  
Jay Hawkstead  
Jessica V Hayashi  
Christine Hayes  
Joan Hebdon  
Ralph D Heckard  
Elizabeth Henderson  
R B Henry  
Amanda Hessels  
Margaret T Hessler  
Xiomara Z Hewitt-Jeffrey  
Lauren V Hobeatsch  
Jill A Hoffman  
Richard E Hoffman  
Darrel Holmes  
Mark Holodny  
Paul D Holton  
Robert S Holzman  
John Hood  
Thomas M Hooton  
Michelle Hulst Stevens  
Hilary Humphreys  
W C Huskins  
Jackeline Iacovella  
Rosemary Ikram  
Mark Ingeman  
Christopher W Ingram  
Martha Iwanoto  
Mary Anne Jackson  
Jesse T Jacob

Reshne D'Incsa  
Jeanne Dixon  
Susan Dolan  
Patrick Dolce  
Susan V Donohue  
Gemma Downham  
Marylene J Dush  
Richard J Duma  
Dennis E Durieux  
Beth Dziekan  
Charles E Edmonson  
Theodore C Eickhoff  
Floyd P Eisenberg  
Cindy Eling  
Katharine Ellingson  
Sean P Elliott  
Richard T Ellison  
Mamoun Elsheikh  
Alexis M Elward  
David L Emanuel  
John M Emmit  
Carol F Encarnacion  
Kylie Enfield  
Judith F English  
Kim S Erlich  
F. Richard Ervin  
Maria C Espiritu-Fuller  
Patricia A Evans  
Mohamad G Fakhri  
Pamela Falk  
Ahmed O Farooq  
Sergio R Filho  
Lori Finkelstein  
Catherine R Fischer  
David T Fisk  
Fidelmis Fitzpatrick  
Silvia S Fonseca  
Barry C Fox  
Henry Framow  
Victoria J Fraser  
Leah W Frederick  
Charles Frenette  
Elizabeth C Frenzel  
Scott K Fridkin  
Candace Friedman  
Teresa M Fulton  
Keiichi Furukawa  
E. Yoko Furuya  
Elizabeth Fuss  
Sylvia Garcia-Houchens  
Moresy Gardner  
Steven E Gardner  
Joseph G Garner  
Kathleen A Gasse  
Petra Gastmeier  
Michael Gaudes  
Daniel J Geha  
Michael S Gelfand  
Angela Gentile  
Dale N Gerding  
Daniel H Gerovich  
Paula Ghazarian  
Jane C Gilbert-Howard  
Joseph Gillis

Show your support! Donate today at [www.shea-online.org](http://www.shea-online.org)

Show your support! Donate today at [www.shea-online.org](http://www.shea-online.org)





# SHEA

The Society for Healthcare Epidemiology of America

- |                       |                         |                         |                         |                          |                      |
|-----------------------|-------------------------|-------------------------|-------------------------|--------------------------|----------------------|
| Susan J Jacobson      | Anna S Levin            | Mark A Miller           | Jennifer Peeples        | Guillermo Saurina        | Susan P Taylor       |
| William R Jarvis      | Steven M Lewis          | Shawn Mills             | David A Pegues          | Joyce Saue               | Bernard R Tegtmeier  |
| Waleed Javadi         | Allison Liddell         | Lona Mody               | Michael E Pelczar       | William Schaffner        | Patrick Tennican     |
| Jaspaul S Jawanda     | Andrew Lin              | Nathalie A Moniot-Ville | Carol Pelletier         | Tammy Schaffner          | Kerri Thom           |
| Timothy C Jenkins     | Matthew Linam           | Elizabeth Monsees       | Robert K Pelz           | David N Scheck           | Debra L Thompson     |
| John Jernigan         | Janice M Lindsey        | Marisa Montecalvo       | Robert G Penn           | Darryl Schultz           | Rodney L Thompson    |
| Victor E Jimenez      | Egill Lingaas           | Ignacio Morales         | Cheryl Perego           | Roland Schultze-Robbecke | William M Thompson   |
| A. Mark Joffe         | Darren R Linkin         | Ana Moran               | Jerry D Peterie         | David N Schwartz         | Emily Thorell        |
| Joseph F John Jr      | Robyn A Livingston      | Beth L Morey            | John W Peterson         | William A Schwartzman    | Terri P Thuotte      |
| Michael A John        | Lawrence Livornese      | Daniel Morgan           | Lance R Peterson        | Marin L Schweizer        | Joseph Thurm         |
| David R Johnson       | Nancy Loge              | Gloria C Morrell        | Robert L Pinsky         | Steven J Schwein         | Susan Tillman        |
| Laura E Johnson       | David J Looney          | Thomas Morris           | Hari M Polenakovic      | Steven Schwimmer         | Philip Toltzis       |
| James G Johnson       | Anthony Lopez           | Allan J Morrison Jr     | Ronald E Polk           | Gail Scully              | Carlos Torres-Viera  |
| Steven M Johnson      | Joaquin Lopez-Contreras | Jose L Munoz            | David J Pombo           | Stephen D Sears          | Francesca J Torriani |
| Stuart F Johnson      | Ted Louie               | Jerome L Murillo        | William F Pomputius III | Rita L Secola            | MaryAnn P Tran       |
| Brenda Jones          | Roger Lovell            | Sheila A Murphey        | Alice Pong              | Joseph J Segal           | Polly Trexler        |
| Jeffrey C Jones       | Franklin D Lowy         | Denise M Murphy         | Aurora E Pop-Vicas      | Marisel Segarra-Newnham  | Karen Trimberger     |
| Lynwood A Jones III   | Michael Luchi           | Cathryn Murphy          | Susan M Poutanen        | John Segreti             | Janice Troeger       |
| W. Patrick Joseph     | Ben Luchsinger          | Cora E Musial           | Lorraine Power          | Lynne M Sehulster        | Carol Tully          |
| Prajwol Joshi         | Sarah J Lulloff         | Carlene Muto            | Burt Prater             | Jeffery D Semel          | Kazuo Umezama        |
| Paul M Jost           | Nancy K Lumley          | Angela L Myers          | Jana Preis              | Edward J Septimus        | Craig A Umscheid     |
| Robin L Jump          | Tammy S Lundstrom       | Frank Myers             | Connie S Price          | Maria Teresa Seville     | Prity S Vaidya       |
| Sharyn S Juneau       | S.W. Lynn               | Joseph M Mylotte        | Margaret F Price        | Ulrich Seybold           | Victoria Valls       |
| Paul F Jurgensen      | Shari Lyons             | Howard A Nadworny       | Amy L Priddy            | Rebecca Shadowen         | J. H van Zeijl       |
| Barbara Juzaitis      | Xiaojun Ma              | Daniel A Nafziger       | Jose R Prieto           | Victoria Shaffer         | Jason Vance          |
| Steve B Kalish        | Alexandra Madison       | John P Narro            | Erica R Pryor           | Roy Shannon              | Philippe Vanhems     |
| Alexander J Kallen    | Joanne T Maffei         | Josephine A Nawaz-Ng    | Gina Pugliese           | Raja Shekar              | Glenda B VanHouten   |
| Ravi K Kamepalli      | Dennis G Maki           | Melinda Neuhart         | Yoram A Puius           | Mark A Shelly            | Jose E Vasquez       |
| Lynne Karant          | Anurag Mahajan          | Ashley M Newberry       | Caroline Quach          | Mark M Shelton           | Joseph Vayalunkal    |
| Marie Kaviratna       | Preeti Malhotra         | Paul M Newberry         | Z. A Quraishi           | Erica S Sherry           | Kees Verdaan         |
| Kevin Kaza            | Elizabeth K Mammen      | Jason Newland           | Ruth A Rabinovitch      | Shirley Shores           | Robert Verley        |
| Carol A Kauffman      | Catenna Maresca         | David Nichols           | V Ramasubramanian       | Nabin K Shrestha         | Kerrie VerLee        |
| John Kaubswener       | Vikas Manchanda         | Roger E Niemeyer        | Vadakepat Ramgopal      | Dawn M Shriver           | Marie V Villages     |
| James M Keegan        | Farrin A Manick         | Judith Nobe-Wang        | Keith M Ramsey          | Coati D Shriver          | Tammy Q Vintilo      |
| Susan M Keller        | Mary L Manning          | Gary A Noskin           | Lawrence Ramunno        | Bryan P Simmonds         | Andrew Vose          |
| Alison A Kelly        | Susan Marchione         | Yoko Nukunin            | Nathaniel Ratnasamy     | Kari Simonsen            | Barbara H Wade       |
| John J Kelly          | Luis A Marcano          | Brenda A Nuse           | Jan Rattemer            | Francis S Smyth          | James S Wade         |
| Mirabelle Kelly       | John A Mariani          | Christine J Neuberger   | Beth Raucher            | John T Srinivasan        | Carol Wagner         |
| Nicole Kieny          | Nedra D Mariani         | Ann-Christine Nyquist   | Karen A Ravin           | William W Srinivasan     | Daniel R Walker      |
| Thomas M Kierkegaard  | Steven I Markson        | Donna L O'Brien         | S.M. Ray                | Sarah S Staiger          | Frank R Walker       |
| Douglas S Kirkpatrick | David B Martin          | Mary C O'Connor         | Terri Rebmann           | Fiona Sraha              | Laraine L Walker     |
| Fred Kirsch           | Emily T Markov          | Randy Odoms             | Luther V Rhodes III     | Stephanie Smith          | Joan Webster         |
| Thomas F Kivimaki     | William J Martone       | Christopher A O'Neil    | Sally Rhodes            | Michael J Smith          | Gina Wickham         |
| Rashida A Kivimaki    | Anne G Maloney          | Michael O O'Neil        | Bruce S Ribner          | Randall Smith            | Azalea Wedg          |
| Gajendra K Khatri     | Frauke Matten           | Edward C O'Neil         | Daniel R Ricciuto       | Graham M Snyder          | Klaus Weier          |
| Amir K Khorram-Roshan | John May                | Russell Olmstead        | Thomas D Rifkin         | Stephen J Sokalski       | Michael Whitfair     |
| Dania Kiani           | Jeannmarie Mayhew       | Margaret A Olsen        | Gary V Riley            | Steven W Sorresyn        | James D Whitehouse   |
| Jeffrey T King        | C. Glen Mayhew          | James B McQuinn         | Brad E Robinson         | Barbara M Skolay         | Gregory Whitley      |
| Mark King             | Patrick A Mayorga       | Maribel Olivo           | Edward N Robinson Jr    | Michael R Spence         | Marc Whittman        |
| Jean W Kinn           | Joanne K May            | Joel D Klein            | Philip A Robinson       | Bruce A Olson            | Todd R Whitin        |
| Arthur W Kintz        | Brynn B Kirkland        | Joseph J Kim            | Maritani Rocha          | Prasad Sreeramou         | Joan M Wideman       |
| Polly A Klink         | Joseph D Klein          | Douglas Kline           | Cynthia L Rodd          | Vijal K Srivastava       | Arthur Williams      |
| Linca L W Klimek      | Matthew W Klimek        | Jeffrey D Kling         | Milerva N Rodriguez     | Ash M Stamm              | Polly A Williams     |
| Linca L W Klimek      | Matthew W Klimek        | James E Knapp           | Gregory W Rose          | Gail L Stanley           | Linda L Winston      |
| Linca L W Klimek      | Matthew W Klimek        | Cheryl K McDonald       | Patricia A Rosenbaum    | Richard Starin           | Matthew Wise         |
| Linca L W Klimek      | Matthew W Klimek        | Allison J McGee         | Victor D Rosenthal      | Jonathan B Starr         | Carolei Rosevear     |
| Linca L W Klimek      | Matthew W Klimek        | Paul C McGovern         | Carol Rosevear          | Therese Staub-Schmidt    | Lawrence A Ross      |
| Linca L W Klimek      | Matthew W Klimek        | John E McGowan Jr       | Jack W Ross             | James P Steinberg        | Virginia Roth        |
| Linca L W Klimek      | Matthew W Klimek        | Paul A McHenry          | Lawrence A Ross         | John J Stern             | Luis Ostrosky        |
| Linca L W Klimek      | Matthew W Klimek        | David S McKinsey        | Virginia Roth           | Ken B Stevenson          | Jan Otter            |
| Linca L W Klimek      | Matthew W Klimek        | Joel P McKinsey         | Brenda J Roup           | Patsy Stinchfield        | Mark D Rowland       |
| Linca L W Klimek      | Matthew W Klimek        | Maria Clara Padoveze    | Mark D Rowland          | Nimalie D Stone          | Haining Rueden       |
| Linca L W Klimek      | Matthew W Klimek        | Ben Painter             | James S Ruckack         | Patricia Stone           | James S Ruckack      |
| Linca L W Klimek      | Matthew W Klimek        | Scott Paparello         | Angela Rupp             | Alivia Strawn            | Stephen Streed       |
| Linca L W Klimek      | Matthew W Klimek        | Jorge P Parada          | Barbara Russell         | Stephen Streed           | Kim Strozzyk         |
| Linca L W Klimek      | Matthew W Klimek        | Stephen Parodi          | William A Rutala        | Richard Starin           | William A Rutala     |
| Linca L W Klimek      | Matthew W Klimek        | Michael F Parry         | Alison L Sabel          | John J Suter             | Stephen Strozzyk     |
| Linca L W Klimek      | Matthew W Klimek        | Catherine Passarelli    | Peggy A SaBell          | Kathryn N Suh            | Carol Sullis         |
| Linca L W Klimek      | Matthew W Klimek        | Marilynn P Patel        | Naisia Saldar           | William A Suter          | William A Suter      |
| Linca L W Klimek      | Matthew W Klimek        | Hema Paul               | Sanjay Saint            | Mark A Swancutt          | James F Swendick     |
| Linca L W Klimek      | Matthew W Klimek        | Sindy M Paul            | Maude Saint-Jean        | James F Swendick         | Emily Sydnor         |
| Linca L W Klimek      | Matthew W Klimek        | Andrew T Pavia          | Jo-Anne M Salangsang    | Thomas A Taft            | Thomas A Taft        |
| Linca L W Klimek      | Matthew W Klimek        | Helene M Paxton         | Linda Salinas           | Sheela Talwar            | Michael J Tan        |
| Linca L W Klimek      | Matthew W Klimek        | Michele L Pearson       | John H Samies           | Emily Sydnor             | Peter C Taylor       |
| Linca L W Klimek      | Matthew W Klimek        |                         | Pablo J Sanchez         | Thomas A Taft            |                      |
| Linca L W Klimek      | Matthew W Klimek        |                         | Thomas J Sandora        | Sheela Talwar            |                      |
| Linca L W Klimek      | Matthew W Klimek        |                         | Raman Sardana           | Michael J Tan            |                      |
| Linca L W Klimek      | Matthew W Klimek        |                         |                         | Peter C Taylor           |                      |

Show your support! Donate today at [www.shea-online.org](http://www.shea-online.org)







# INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY


## Call for Manuscripts: The Role of the Environment in Infection Prevention

*Infection Control and Hospital Epidemiology (ICHE)* is pleased to announce that it will publish a peer-reviewed, special topic issue devoted to the role of the environment in infection prevention and healthcare epidemiology. This issue will be published in conjunction with the spring meeting of the Society for Healthcare Epidemiology of America ([www.shea-online.org](http://www.shea-online.org)) to be held in Atlanta, Georgia, May 2013. This conference will include a forum on the role of the environment that will bring together leaders from a variety of healthcare settings to discuss current research, effective strategies, and future research agendas.

**Of particular interest are papers that address the following:**

- Sanitization and disinfection: methods and technology, device quality and process improvement
- How to clean and disinfect the environment: methods and technology, quality and process improvement, daily vs. terminal cleaning
- The role of the environmental reservoir in transmission and autonomy of specific organisms, and methods of control (e.g. MRSA, C. difficile, and Legionella)
- Decolonization of patients to prevent specific infectious syndromes (e.g. BEI, VSI or ICI) and specific organisms (e.g. MRSA, E. coli)
- Related issues in different patient populations (e.g. pediatric, geriatric) or special units (e.g. ICU, ED, long-term, long-stay or non-acute care settings)
- Architectural design, construction, and renovation – environmental considerations for infection prevention

Authors are invited to submit their work electronically via Editorial Manager ([www.editorialmanager.com/ichj](http://www.editorialmanager.com/ichj)) no later than **October 1, 2012**. Research papers in the form of original articles (up to 3,000 words), concise communications (up to 1,200 words) and reviews (up to 600 words) will be considered for review.



For manuscript preparation details, please see "For Contributors" at [www.journals.uchicago.edu/ICHE](http://www.journals.uchicago.edu/ICHE) or contact the editorial office at [iche@press.uchicago.edu](mailto:iche@press.uchicago.edu).

Suzanne Bradley, MD, MPH  
Infection Control and Hospital  
Epidemiology






“An accessible and gripping narrative on a serious topic that manages to explain, in plain English, how viruses are changing the world.”—NATHAN WOLFE, founder and CEO of Global Viral Forecasting

# A Planet of **Viruses**

CARL ZIMMER



“*A Planet of Viruses* is an important primer on the viruses living within and around all of us—sometimes funny, other times shocking, and always accessible. Whether discussing the common cold and flu, little-known viruses that attack bacteria or protect oceans, or the world’s viral future as seen through our encounters with HIV or SARS, Zimmer’s writing is lively, knowledgeable, and graced with poetic touches.”

—REBECCA SKLOOT, author of *The Immortal Life of Henrietta Lacks*


**Cloth \$20.00**

The University of Chicago Press [www.press.uchicago.edu](http://www.press.uchicago.edu)



Included in CMS/JCAHO  
Core Measures for CAP\*

# An IV Cephalosporin Approved for



caused by known or suspected *S. pneumoniae*

## USAGE

- To reduce the development of drug-resistant bacteria and maintain the effectiveness of TEFLARO® and other antibacterial drugs, TEFLARO should be used to treat only CABP that is proven or strongly suspected to be caused by susceptible bacteria.
- When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

## INDICATION

- TEFLARO is indicated for the treatment of community-acquired bacterial pneumonia (CABP) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: *Streptococcus pneumoniae* (including cases with concurrent bacteremia), *Staphylococcus aureus* (methicillin-susceptible isolates only), *Haemophilus influenzae*, *Moraxella pneumoniae*, *Klebsiella oxytoca*, and *Escherichia coli*.

## IMPORTANT SAFETY INFORMATION

### Contraindications

- TEFLARO is contraindicated in patients with known serious hypersensitivity to ceftriaxone or other members of the cephalosporin class. Anaphylaxis and anaphylactoid reactions have been reported with ceftriaxone.

TEFLARO (ceftaroline fosamil) is one of the recommended β-lactam antibiotics for Community-Acquired Pneumonia in Immunocompetent Patients—Non-ICU Patients, PN-6, Gab-6, Specifications Manual for National Hospital Inpatient Quality Measures, Version 4.0, Discharges 01-01-12 (1Q12) through 06-30-12 (2Q12).

Joint Commission on Accreditation of Healthcare Organizations (JCAHO) is now known as The Joint Commission. CMS=Centers for Medicare and Medicaid Services.

Please see additional Important Safety Information throughout and brief summary of Prescribing Information on last page of this advertisement.

Please also see full Prescribing Information at [www.TEFLARO.com](http://www.TEFLARO.com).

## Warnings and Precautions

### Hypersensitivity Reactions

- Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported with beta-lactam antibacterials. Before therapy with TEFLARO is instituted, careful inquiry about previous hypersensitivity reactions to other cephalosporins, penicillins, or carbapenems should be made. If this product is to be given to a penicillin- or other beta-lactam-allergic patient, caution should be exercised because cross sensitivity among beta-lactam antibacterial agents has been clearly established.

- If an allergic reaction to TEFLARO occurs, the drug should be discontinued. Serious acute hypersensitivity (anaphylactic) reactions require emergency treatment with epinephrine and other emergency measures that may include airway management, oxygen, intravenous fluids, antihistamines, corticosteroids, and vasopressors as clinically indicated.

**Teflaro**  
(ceftaroline fosamil) for injection  
600 mg • 400 mg

\*TEFLARO (ceftaroline fosamil) is on the list of Recommended β-lactam Antibiotics for Community-Acquired Pneumonia in Immunocompetent Patients—Non-ICU Patients, PN-6, Gab-6, Specifications Manual for National Hospital Inpatient Quality Measures, Version 4.0, Discharges 01-01-12 (1Q12) through 06-30-12 (2Q12).  
Joint Commission on Accreditation of Healthcare Organizations (JCAHO) is now known as The Joint Commission. CMS=Centers for Medicare and Medicaid Services.  
Please see additional Important Safety Information throughout and brief summary of Prescribing Information on last page of this advertisement.  
Please also see full Prescribing Information at [www.TEFLARO.com](http://www.TEFLARO.com).



# Broad-spectrum cephalosporin coverage



## INDICATION AND USAGE

- TEFLARO is indicated for the treatment of **community-acquired bacterial pneumonia (CABP)** caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: *Streptococcus pneumoniae* (including cases with concurrent bacteremia), *Staphylococcus aureus* (methicillin-susceptible isolates only), *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Klebsiella oxytoca*, and *Escherichia coli*.
- To reduce the development of drug-resistant bacteria and maintain the effectiveness of TEFLARO and other antibacterial drugs, TEFLARO should be used to treat only CABP that is proven or strongly suspected to be caused by susceptible bacteria. Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to ceftaroline. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

## IMPORTANT SAFETY INFORMATION (continued)

### **Clostridium difficile-associated Diarrhea**

- Clostridium difficile*-associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including TEFLARO, and may range in severity from mild diarrhea to fatal colitis. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents. If CDAD is suspected or confirmed, antibacterials not directed against *C. difficile* should be discontinued, if possible.

### **Direct Coombs' Test Seroconversion**

- Seroconversion from a negative to a positive direct Coombs' test result occurred in 120/1114 (10.8%) of patients receiving TEFLARO and 49/1116 (4.4%) of patients receiving comparator drugs in the four pooled Phase 3 trials. No adverse reactions representing hemolytic anemia were reported in any treatment group. If anemia develops during or after treatment with TEFLARO, drug-induced hemolytic anemia should be considered. If drug-induced hemolytic anemia is suspected, discontinuation of TEFLARO should be considered and supportive care should be administered to the patient if clinically indicated.

### **Development of Drug-Resistant Bacteria**

- Prescribing TEFLARO in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

## Adverse Reactions

- In the four pooled Phase 3 clinical trials, serious adverse events occurred in 98/1300 (7.5%) of patients receiving TEFLARO and 100/1297 (7.7%) of patients receiving comparator drugs. Treatment discontinuation due to adverse events occurred in 35/1300 (2.7%) of patients receiving TEFLARO and 48/1297 (3.7%) of patients receiving comparator drugs with the most common adverse events leading to discontinuation being hypersensitivity for both treatment groups at a rate of 0.3% in the TEFLARO group and 0.5% in the comparator group.
- No adverse reactions occurred in greater than 5% of patients receiving TEFLARO. The most common adverse reactions occurring in >2% of patients receiving TEFLARO in the pooled Phase 3 clinical trials were diarrhea, nausea, and rash.

## Drug Interactions

- No clinical drug-drug interaction studies have been conducted with TEFLARO. There is minimal potential for drug-drug interactions between TEFLARO and CYP450 substrates, inhibitors, or inducers; drugs known to undergo active renal secretion; and drugs that may alter renal blood flow.

## Use in Specific Populations

- TEFLARO has not been studied in pregnant women. Therefore, TEFLARO should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.
- It is not known whether ceftaroline is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TEFLARO is administered to a nursing woman.
- Safety and effectiveness in pediatric patients have not been established.
- Because elderly patients, those  $\geq 65$  years of age, are more likely to have decreased renal function and ceftaroline is excreted primarily by the kidney, care should be taken in dose selection in this age group and it may be useful to monitor renal function. Dosage adjustment for elderly patients should therefore be based on renal function.
- Dosage adjustment is required in patients with moderate (CrCl >30 to  $\leq 50$  mL/min) or severe (CrCl  $\geq 15$  to  $\leq 30$  mL/min) renal impairment and in patients with end-stage renal disease (CrCl <15 mL/min).
- The pharmacokinetics of ceftaroline in patients with hepatic impairment have not been established.

Please see brief summary of Prescribing Information on following page.  
Please also see full Prescribing Information at [www.TEFLARO.com](http://www.TEFLARO.com).



© 2011 Forest Laboratories, Inc. 69-12000198-C 11/11

**Teflaro**   
(ceftaroline fosamil) for injection  
600 mg • 400 mg



**INDICATIONS AND USAGE:** Teflaro® (ceftaroline fosamil) is indicated for the treatment of patients with the following infections caused by susceptible isolates of the designated microorganisms. **Acute Bacterial Skin and Skin Structure Infections** - Teflaro is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: *Staphylococcus aureus* (including methicillin-susceptible and -resistant isolates), *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Escherichia coli*, *Klebsiella pneumoniae*, and *Klebsiella oxytoca*. **Community-Acquired Bacterial Pneumonia** - Teflaro is indicated for the treatment of community-acquired bacterial pneumonia (CABP) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: *Streptococcus pneumoniae* (including cases with concurrent bacteremia), *Staphylococcus aureus* (methicillin-susceptible isolates only), *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Klebsiella oxytoca*, and *Escherichia coli*. **Usage** - To reduce the development of drug-resistant bacteria and maintain the effectiveness of Teflaro and other antibacterial drugs, Teflaro should be used to treat only ABSSSI or CABP that are proven or strongly suspected to be caused by susceptible bacteria. Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to ceftaroline. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

**CONTRAINDICATIONS:** Teflaro is contraindicated in patients with known serious hypersensitivity to ceftaroline or other members of the cephalosporin class. Anaphylaxis and anaphylactoid reactions have been reported with ceftaroline.

**WARNINGS AND PRECAUTIONS: Hypersensitivity Reactions** - Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterials. Before therapy with Teflaro is instituted, careful inquiry about previous hypersensitivity reactions to other cephalosporins, penicillins, or carbapenems should be made. If this product is to be given to a penicillin- or other beta-lactam-allergic patient, caution should be exercised because cross sensitivity among beta-lactam antibacterial agents has been clearly established. If an allergic reaction to Teflaro occurs, the drug should be discontinued. Serious acute hypersensitivity (anaphylactic) reactions require emergency treatment with epinephrine and other emergency measures, that may include airway management, oxygen, intravenous fluids, antihistamines, corticosteroids, and vasopressors as clinically indicated. **Clostridium difficile-associated Diarrhea** - *Clostridium difficile*-associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including Teflaro, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of *C. difficile*. *C. difficile* produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents. If CDAD is suspected or confirmed, antibacterials not directed against *C. difficile* should be discontinued, if possible. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated [see Adverse Reactions]. **Direct Coombs' Test Seroconversion** - Seroconversion from a negative to a positive direct Coombs' test result occurred in 120/1114 (10.8%) of patients receiving Teflaro and 49/1116 (4.4%) of patients receiving comparator drugs in the four pooled Phase 3 trials. In the pooled Phase 3 CABP trials, 51/520 (9.8%) of Teflaro-treated patients compared to 24/534 (4.5%) of ceftriaxone-treated patients seroconverted from a negative to a positive direct Coombs' test result. No adverse reactions representing hemolytic anemia were reported in any treatment group. If anemia develops during or after treatment with Teflaro, drug-induced hemolytic anemia should be considered. Diagnostic studies including a direct Coombs' test, should be performed. If drug-induced hemolytic anemia is suspected, discontinuation of Teflaro should be considered and supportive care should be administered to the patient (i.e. transfusion) if clinically indicated.

**Development of Drug-Resistant Bacteria** - Prescribing Teflaro in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

**ADVERSE REACTIONS:** The following serious events are described in greater detail in the Warnings and Precautions section: Hypersensitivity reactions; *Clostridium difficile*-associated diarrhea; Direct Coombs' test seroconversion. **Adverse Reactions from Clinical Trials** - Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be compared directly to rates from clinical trials of another drug and may not reflect rates observed in practice. Teflaro was evaluated in four controlled comparative Phase 3 clinical trials (two in ABSSSI and two in CABP) which included 1300 adult patients treated with Teflaro (600 mg administered by IV over 1 hour every 12h) and 1297 patients treated with comparator (vancomycin plus aztreonam or ceftriaxone) for a treatment period up to 21 days. The median age of patients treated with Teflaro was 54 years, ranging between 18 and 99 years old. Patients treated with Teflaro were predominantly male (63%) and Caucasian (82%). **Serious Adverse Events and Adverse Events Leading to Discontinuation** - In the four pooled Phase 3 clinical trials, serious adverse events occurred in 98/1300 (7.5%) of patients receiving Teflaro and 100/1297 (7.7%) of patients receiving comparator drugs. The most common SAEs in both the Teflaro and comparator treatment groups were in the respiratory and infection system organ classes (SOC). Treatment discontinuation due to adverse events occurred in 35/1300 (2.7%) of patients receiving Teflaro and 48/1297 (3.7%) of patients receiving comparator drugs with the most common adverse events leading to discontinuation being hypersensitivity for both treatment groups at a rate of 0.3% in the Teflaro group and 0.5% in comparator group. **Most Common Adverse Reactions** - No adverse reactions occurred in greater than 5% of patients receiving Teflaro. The most common adverse

reactions occurring in > 2% of patients receiving Teflaro in the pooled phase 3 clinical trials were diarrhea, nausea, and rash. Table 4 in the full prescribing information lists adverse reactions occurring in ≥ 2% of patients receiving Teflaro in the pooled Phase 3 clinical trials (two in ABSSSI and two in CABP). The first value displays the percentage of patients in the pooled Teflaro trials (N=1300) and the second shows the percentage in the Pooled Comparators<sup>a</sup> trials (N=1297). **Gastrointestinal disorders:** Diarrhea (5%, 3%), Nausea (4%, 4%), Constipation (2%, 2%), Vomiting (2%, 2%); **Investigations:** Increased transaminases (2%, 3%); **Metabolism and nutrition disorders:** Hypokalemia (2%, 3%); **Skin and subcutaneous tissue disorders:** Rash (3%, 2%); **Vascular disorders:** Phlebitis (2%, 1%)\* Comparators included vancomycin 1 gram IV every 12h plus aztreonam 1 gram IV every 12h in the Phase 3 ABSSSI trials, and ceftriaxone 1 gram IV every 24h in the Phase 3 CABP trials. **Other Adverse Reactions Observed During Clinical Trials of Teflaro** - Following is a list of additional adverse reactions reported by the 1740 patients who received Teflaro in any clinical trial with incidences less than 2%. Events are categorized by System Organ Class. **Blood and lymphatic system disorders** - Anemia, Eosinophilia, Neutropenia, Thrombocytopenia; **Cardiac disorders** - Bradycardia, Palpitations; **Gastrointestinal disorders** - Abdominal pain; **General disorders and administration site conditions** - Pyrexia; **Hepatobiliary disorders** - Hepatitis; **Immune system disorders** - Hypersensitivity, Anaphylaxis; **Infections and infestations** - *Clostridium difficile* colitis; **Metabolism and nutrition disorders** - Hypoglycemia, Hyperkalemia; **Nervous system disorders** - Dizziness, Convulsion; **Renal and urinary disorders** - Renal failure; **Skin and subcutaneous tissue disorders** - Urticaria.

**DRUG INTERACTIONS:** No clinical drug-drug interaction studies have been conducted with Teflaro. There is minimal potential for drug-drug interactions between Teflaro and CYP450 substrates, inhibitors, or inducers; drugs known to undergo active renal secretion; and drugs that may alter renal blood flow [see Clinical Pharmacology].

**USE IN SPECIFIC POPULATIONS: Pregnancy Category B** - Developmental toxicity studies performed with ceftaroline fosamil in rats at IV doses up to 300 mg/kg demonstrated no maternal toxicity and no effects on the fetus. A separate toxicokinetic study showed that ceftaroline exposure in rats (based on AUC) at this dose level was approximately 8 times the exposure in humans given 600 mg every 12 hours. There were no drug-induced malformations in the offspring of rabbits given IV doses of 25, 50, and 100 mg/kg, despite maternal toxicity. Signs of maternal toxicity appeared secondary to the sensitivity of the rabbit gastrointestinal system to broad-spectrum antibacterials and included changes in fecal output in all groups and dose-related reductions in body weight gain and food consumption at ≥ 50 mg/kg; these were associated with an increase in spontaneous abortion at 50 and 100 mg/kg. The highest dose was also associated with maternal morbidity and mortality. An increased incidence of a common rabbit skeletal variation, angulated hyoid alae, was also observed at the maternally toxic doses of 50 and 100 mg/kg. A separate toxicokinetic study showed that ceftaroline exposure in rabbits (based on AUC) was approximately 0.8 times the exposure in humans given 600 mg every 12 hours at 25 mg/kg and 1.5 times the human exposure at 50 mg/kg. Ceftaroline fosamil did not affect the postnatal development or reproductive performance of the offspring of rats given IV doses up to 450 mg/kg/day. Results from a toxicokinetic study conducted in pregnant rats with doses up to 300 mg/kg suggest that exposure was ≥ 8 times the exposure in humans given 600 mg every 12 hours. There are no adequate and well-controlled trials in pregnant women. Teflaro should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. **Nursing Mothers** - It is not known whether ceftaroline is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Teflaro is administered to a nursing woman. **Pediatric Use** - Safety and effectiveness in pediatric patients have not been established. **Geriatric Use** - Of the 1300 patients treated with Teflaro in the Phase 3 ABSSSI and CABP trials, 397 (30.5%) were ≥ 65 years of age. The clinical cure rates in the Teflaro group (Clinically Evaluable [CE] Population) were similar in patients ≥ 65 years of age compared with patients < 65 years of age in both the ABSSSI and CABP trials. The adverse event profiles in patients ≥ 65 years of age and in patients < 65 years of age were similar. The percentage of patients in the Teflaro group who had at least one adverse event was 52.4% in patients ≥ 65 years of age and 42.8% in patients < 65 years of age for the two indications combined. Ceftaroline is excreted primarily by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in this age group and it may be useful to monitor renal function. Elderly subjects had greater ceftaroline exposure relative to non-elderly subjects when administered the same single dose of Teflaro. However, higher exposure in elderly subjects was mainly attributed to age-related changes in renal function. Dosage adjustment for elderly patients should be based on renal function [see Dosage and Administration and Clinical Pharmacology]. **Patients with Renal Impairment** - Dosage adjustment is required in patients with moderate (CrCl > 30 to ≤ 50 mL/min) or severe (CrCl ≤ 15 to ≤ 30 mL/min) renal impairment and in patients with end-stage renal disease (ESRD - defined as CrCl < 15 mL/min), including patients on hemodialysis (HD) [see Dosage and Administration and Clinical Pharmacology].

**OVERDOSAGE:** In the event of overdose, Teflaro should be discontinued and general supportive treatment given. Ceftaroline can be removed by hemodialysis. In subjects with ESRD administered 400 mg of Teflaro, the mean total recovery of ceftaroline in the dialysate following a 4-hour hemodialysis session started 4 hours after dosing was 76.5 mg (21.6% of the dose). However, no information is available on the use of hemodialysis to treat overdose [see Clinical Pharmacology].

**Distributed by:**

Forest Pharmaceuticals, Inc.  
Subsidiary of Forest Laboratories, Inc.  
St. Louis, MO 63045, USA

Teflaro is a registered trademark of Forest Laboratories, Inc.

**IF95USCFR05**

Revised: May 2012

© 2010, 2011 Forest Laboratories, Inc. All rights reserved.

069-1300079-BS-A-MAY12

Please also see full Prescribing Information at [www.teflaro.com](http://www.teflaro.com).





 **Emerald Journals**

## Clinical Governance

*An International Journal*

*Clinical Governance: An International Journal* aims to address the doubts, queries, triumphs and practical applications of introducing quality assurance mechanisms into the delivery of care.

The journal takes an international stance and covers key developments worldwide which can inform best practice in health care. Efficiency, effectiveness and economics are the main factors in the assessment of best practice and all are addressed in the research- audit- and evidence-based papers published. All papers are peer reviewed to ensure their validity and value to current debates.

### **The journal publishes:**

- Research articles which illustrate clear implications for practice
- Results-focused case studies which discuss problems and successes in clinical governance techniques
- Special issues on topical themes

For more information please visit the homepage:  
[www.emeraldinsight.com/cgij.htm](http://www.emeraldinsight.com/cgij.htm)

To submit a paper visit:  
<http://mc.manuscriptcentral.com/cgij>



Research you can use




## Join SHEA

---

Access to the information you need to meet the infection prevention challenges ahead.

- One year subscription to *Infection Control & Hospital Epidemiology*
- Online access to *Infection Control & Hospital Epidemiology*
- Monthly newsletter with abstracts of scientific journal articles and current events
- Online job board
- Online member search
- Continuing Medical Education (CME) and Continuing Nursing Education (CNE) opportunities



## About SHEA

---

The Society for Healthcare Epidemiology of America (SHEA) was founded in 1980 to advance the science of healthcare epidemiology and infection prevention. SHEA works to maintain the utmost quality of patient care and healthcare worker safety in all healthcare settings, applying epidemiologic principles and prevention strategies to a wide range of quality-of-care issues. SHEA is strengthened by its active membership in all branches of medicine, public health, and healthcare epidemiology. The Society's expertise is sought by healthcare regulatory and accrediting agencies, and its scientific voice is influential in guiding decision-making bodies towards rational, effective, cost-conscious policies.

## Mission

---

SHEA's mission is to prevent and control healthcare-associated infections and advance the field of healthcare epidemiology.

## Core Values

---

SHEA as an organization:

- Advances the science of healthcare epidemiology through research and education
- Translates knowledge into effective policy and practice
- Mentors, trains and promotes professional development in healthcare epidemiology
- Collaborates and shares expertise with other organizations
- Adheres to high ethical standards and promotes honesty and ethical principles in the practice of epidemiology

## Areas of Focus

---

- Epidemiologic research and laboratory investigation
- Applying the best evidence for protecting patients and reporting data
- Risk reduction programs focused on device and procedure management
- Policy development and implementation
- Education and information

Please contact [info@shea-online.org](mailto:info@shea-online.org) with membership inquiries.

**Join SHEA at [www.shea-online.org](http://www.shea-online.org)**





# Peace of Mind Matters



## Protection You Can Count On

You have enough to worry about. Choose 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressings, with all-in-one antimicrobial protection and advanced securement, and be confident you're giving your patients the best possible I.V. site care.

For over 30 years, 3M has collaborated with health care professionals around the world to develop products that simplify and improve care practices. To learn more about Tegaderm™ CHG Dressings or the full line of Tegaderm™ Brand I.V. Site Dressings, go to [3M.com/TegadermCHG](http://3M.com/TegadermCHG)

## Tegaderm™ CHG

Part of the Full Line of Tegaderm™ Brand I.V. Site Dressings



©3M 2012. All Rights Reserved. 3M and Tegaderm are trademarks of 3M.